Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group

Cancer

Volumn 119, Issue 21, 2013, Pages 3887-3894

  Gratias, Eric J ^a   Jennings, Lawrence J ^b   Anderson, James R ^c   Dome, Jeffrey S ^d   Grundy, Paul ^e   Perlman, Elizabeth J ^b  

^a TC Thompson Children's Hospital   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

chromosome 1; kidney; pediatrics; prognosis; Wilms tumor

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHROMOSOME 16Q; CHROMOSOME 1P; CHROMOSOME 1Q GAIN; CHROMOSOME LOSS; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEPHROBLASTOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL TIME;

CHROMOSOME 1; KIDNEY; PEDIATRICS; PROGNOSIS; WILMS TUMOR;

CHILD; CHROMOSOME DUPLICATION; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; GENETIC ASSOCIATION STUDIES; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; WILMS TUMOR;

EID: 84886086836     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28239     Document Type: Article

References (36)

1. Bernstein L, Linet M, Smith MA, Olshan AF,. Renal tumors. In:, Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649. Bethesda, MD: Surveillance, Epidemiology, and End Results Program, National Cancer Institute; 1999: 79-90.
2. Beckwith JB, Palmer NF,. Histopathology and prognosis of Wilms tumor: results from the First National Wilms' Tumor Study. Cancer. 1978; 41: 1937-1948.
3. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor-new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol. 1996; 20: 909-920.
4. Gratias EJ, Dome JS,. Current and emerging chemotherapy treatment strategies for Wilms tumor in North America. Pediatr Drugs. 2008; 10: 115-124.
5. D'Angio GJ, Evans AE, Breslow NE, et al. The treatment of Wilms' tumor: results of the national Wilms' tumor study. Cancer. 1976; 38: 633-646.
6. D'Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer. 1981; 47: 2302-2311.
7. D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer. 1989; 64: 349-360.
8. Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1998; 16: 237-245.
9. Green DM, Breslow NE, Beckwith JB, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1998; 16: 3744-3751.
10. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005; 23: 7312-7321.
11. Breslow NE, Palmer NF, Hill LR, Buring J, D'Angio GJ,. Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study. Cancer. 1978; 41: 1577-1589.
12. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC,. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res. 1994; 54: 2331-2333.
13. Green DM, Beckwith JB, Weeks DA, Moksness J, Breslow NE, D'Angio GJ,. The relationship between microsubstaging variables, age at diagnosis, and tumor weight of children with stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor study. Cancer. 1994; 74: 1817-1820.
14. Breslow N, Sharples K, Beckwith JB, et al. Prognostic factors in nonmetastatic, favorable histology Wilms'' tumor. Results of the Third National Wilms'' Tumor Study. Cancer. 1991; 68: 2345-2353.
15. Garcia M, Douglass C, Schlosser JV,. Classification and prognosis in Wilms' tumor. Radiology. 1963; 80: 574-580.
16. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2001; 19: 1926-1934.
17. Warwick AB, Kalapurakal JA, Ou SS, et al. Portal hypertension in children with Wilms' tumor: a report from the National Wilms' Tumor Study Group. Int J Radiat Oncol Biol Phys. 2010; 77: 210-216.
18. Breslow NE, Lange JM, Friedman DL, et al. Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer. 2010; 127: 657-666.
19. Green DM, Lange JM, Peabody EM, et al. Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study. J Clin Oncol. 2010; 28: 2824-2830.
20. Bown N, Cotterill SJ, Roberts P, et al. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol. 2002; 38: 11-21.
21. Williams RD, Al-Saadi R, Natrajan R, et al. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer. 2011; 50: 982-995.
22. MdZin R, Murch A, Charles A,. Cytogenetic findings in Wilms' tumour: a single institute study. Pathology. 2010; 42: 643-649.
23. Kullendorff C-M, Soller M, Wiebe T, Mertens F,. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors. Cancer Genetics Cytogenetics. 2003; 140: 82-87.
24. Natrajan R, Little SE, Sodha N, et al. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol. 2007; 211: 52-59.
25. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol. 2006; 210: 48-58.
26. Huang C-C, Gadd S, Breslow N, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res. 2009; 15: 1770-1778.
27. Williams RD, Hing SN, Greer BT, et al. Prognostic classification of relapsing favorable histology Wilms tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer. 2004; 41: 65-79.
28. Rassekh SR, Chan S, Harvard C, Dix D, Qiao Y, Racjan-Separovic E,. Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays. Cancer Genetics Cytogenetics. 2008; 182: 84-94.
29. Steenman M, Redeker B, de Meulemeester M, et al. Comparative genomic hybridization analysis of Wilms tumors. Cytogenet Cell Genet. 1997; 77: 296-303.
30. Hing S, Lu Y-J, Summersgill B, et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol. 2001; 158: 393-398.
31. Natrajan R, Little SE, Reis-Filho JS, et al. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors. Clin Cancer Res. 2006; 12: 7284-7293.
32. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G,. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30: e57.
33. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
34. Peto R, Peto J,. Asymptotically efficient rank invariant test procedures. J R Stat Soc Series A. 1972; 135: 185-207.
35. Cox DR,. Regression models and life-tables. J R Stat Soc B. 1972; 34: 187-220.
36. Spreafico F, Gandola L, D'Angelo P, et al. AIEOP Wilms Tumor Working Group. Heterogeneity of disease classified as stage III in Wilms tumor: a report from the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Int J Radiat Oncol Biol Phys. 2012; 82: 348-354.